Atlas Trials

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

Clinical trial NCT07080905 · RECRUITING

Trial details

NCT number
NCT07080905
Sponsor
CSL Behring
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Hemophilia B
Start date
2025-07-28
Primary completion
2033-10-24
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.